Crisa2% w/w 10 gm tube

Crisa 2% w/w 10 gm tube is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 3 months of age and older.

Apply a thin layer of Crisa 2% w/w 10 gm tube twice daily to affected areas. Crisa 2% w/w 10 gm tube is for topical use only and not for ophthalmic, oral, or intravaginal use.

In vitro studies using human liver microsomes indicated that under the conditions of clinical use, Crisa 2% w/w 10 gm tube and metabolite 1 are not expected to inhibit cytochrome P450 (CYP) 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4. In vitro human liver microsomes studies for metabolite 2 showed that it did not inhibit activities of CYP2C19, 2D6, and 3A4.

Allergic reactions- Crisa 2% w/w 10 gm tube may cause allergic reactions at or near the application site. These can be serious and may include hives, itching, swelling, and redness. The most common side effect of Crisa 2% w/w 10 gm tube is application site pain, such as burning or stinging.

Hypersensitivity reactions, including contact urticaria have occurred in patients treated with Crisa 2% w/w 10 gm tube. If signs and symptoms of hypersensitivity occur, discontinue Crisa 2% w/w 10 gm tube immediately and initiate appropriate therapy.

Do not store above 30°C temperature. Keep away from light and out of the reach of children.

Topical anti-inflammatory preparations

The active ingredient, Crisa 2% w/w 10 gm tube, is a phosphodiesterase-4 (PDE-4) inhibitor, mainly acting on phosphodiesterase 4B (PDE4B), which causes inflammation. Chemically, Crisa 2% w/w 10 gm tube is a phenoxybenzoxaborole. It contains a boron atom that helps penetrate the skin and is essential for its binding activity. Inhibition of PDE4B appears to suppress the release of tumor necrosis factor alpha (TNFα), interleukin-12 (IL-12), IL-23 and other cytokines, proteins believed to be involved in the immune response and inflammation.

Pregnancy: There is no available data with Crisa 2% w/w 10 gm tube in pregnant women to inform the drug-associated risk for major birth defects and miscarriage. In animal reproduction studies, there were no adverse developmental effects observed with oral administration of Crisa 2% w/w 10 gm tube in pregnant rats and rabbits during organogenesis at doses up to 3 and 2 times, respectively, the maximum recommended human dose (MRHD).Lactation: There is no information available on the presence of Crisa 2% w/w 10 gm tube in human milk. Crisa 2% w/w 10 gm tube is systemically absorbed. The lack of clinical data during lactation precludes a clear determination of the risk of Crisa 2% w/w 10 gm tube to a breastfed infant.